Clinical use of afala in the therapy of chronic prostatitis.
The efficiency of afala in the therapy of chronic abacterial prostatitis was demonstrated. The preparation considerably improved urodynamics, reduced pain syndrome and inflammation, decreased prostate volume, improved patient's quality of life, and restored microcirculation in the prostate. No changes in blood, urine, and ECG parameters were noted. No side effects requiring afala withdrawal were recorded.
Tkachuk
V N
VN
Urology Hospital, I. P. Pavlov State Medical University, St.Petersburg.
D000328:Adult; D000906:Antibodies / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects; D055815:Young Adult
D000906:Antibodies; D007155:Immunologic Factors; C533336:afala